L. Aurisicchio, D. Peruzzi, A. Conforti, S. Dharmapuri, A. Biondo et al., Treatment of Mammary Carcinomas in HER-2 Transgenic Mice through Combination of Genetic Vaccine and an Agonist of Toll-Like Receptor 9, Clinical Cancer Research, vol.15, issue.5, pp.1575-84, 2009.
DOI : 10.1158/1078-0432.CCR-08-2628

H. Cho and D. Leahy, Structure of the extracellular region of ERBB3 reveals an interdomain tether, Science, vol.209, pp.1330-1333, 2002.

D. Easty, S. Gray, O. Byrne, K. , O. Donnell et al., Receptor tyrosine kinases and their activation in melanoma, Pigment Cell & Melanoma Research, vol.106, issue.3, pp.446-61, 2011.
DOI : 10.1111/j.1755-148X.2011.00836.x

E. Djerf, C. Trinks, A. Abdiu, L. Thunell, A. Hallbeck et al., ErbB receptor tyrosine kinases contribute to proliferation of malignant melanoma cells: inhibition by gefitinib (ZD1839), Melanoma Research, vol.19, issue.3, pp.156-66, 2009.
DOI : 10.1097/CMR.0b013e32832c6339

M. Reschke, D. Mihic-probst, E. Van-der-horst, P. Knyazev, P. Wild et al., HER3 Is a Determinant for Poor Prognosis in Melanoma, Clinical Cancer Research, vol.14, issue.16, pp.5188-97, 2008.
DOI : 10.1158/1078-0432.CCR-08-0186

H. Waterman, I. Alroy, S. Strano, R. Seger, and Y. Yarden, The C-terminus of the kinase-defective neuregulin receptor ErbB-3 confers mitogenic superiority and dictates endocytic routing, The EMBO Journal, vol.18, issue.12, pp.3348-58, 1999.
DOI : 10.1093/emboj/18.12.3348

Z. Cao, X. Wu, Y. L. Sweeney, C. Carraway, and K. , Neuregulin-Induced ErbB3 Downregulation Is Mediated by a Protein Stability Cascade Involving the E3 Ubiquitin Ligase Nrdp1, Molecular and Cellular Biology, vol.27, issue.6, 2007.
DOI : 10.1128/MCB.01245-06

K. Schmitz and K. Ferguson, Interaction of antibodies with ErbB receptor extracellular regions, Experimental Cell Research, vol.315, issue.4, pp.659-70, 2009.
DOI : 10.1016/j.yexcr.2008.10.008

J. Albanell, J. Codony, A. Rovira, B. Mellado, and P. Gascón, Mechanism of Action of Anti-Her2 Monoclonal Antibodies: Scientific Update on Trastuzumab and 2c4, Adv Exp Med Biol, vol.532, pp.253-68978, 2003.
DOI : 10.1007/978-1-4615-0081-0_21

M. Franklin, K. Carey, F. Vajdos, D. Leahy, A. De-vos et al., Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex, Cancer Cell, vol.5, issue.4, pp.317-345, 2004.
DOI : 10.1016/S1535-6108(04)00083-2

L. Lugini, P. Matarrese, A. Tinari, F. Lozupone, C. Federici et al., Cannibalism of Live Lymphocytes by Human Metastatic but Not Primary Melanoma Cells, Cancer Research, vol.66, issue.7, pp.3629-3667, 2006.
DOI : 10.1158/0008-5472.CAN-05-3204

T. Smirnova, Z. Zhou, R. Flinn, J. Wyckoff, P. Boimel et al., Phosphoinositide 3-kinase signaling is critical for ErbB3-driven breast cancer cell motility and metastasis, Oncogene, vol.26, issue.6, 2011.
DOI : 10.1038/onc.2011.275

C. Gordon-thomson, J. Jones, R. Mason, and G. Moore, ErbB receptors mediate both migratory and proliferative activities in human melanocytes and melanoma cells, Melanoma Research, vol.15, issue.1, pp.21-29, 2005.
DOI : 10.1097/00008390-200502000-00005

F. Haluska, T. Pemberton, N. Ibrahim, K. Kalinsky, R. The et al., The RTK/RAS/BRAF/PI3K Pathways in Melanoma: Biology, Small Molecule Inhibitors, and Potential Applications, Seminars in Oncology, vol.34, issue.6, pp.546-54, 2007.
DOI : 10.1053/j.seminoncol.2007.09.011

K. Buac, M. Xu, J. Cronin, A. Weeraratna, S. Hewitt et al., NRG1???/???ERBB3 signaling in melanocyte development and melanoma: inhibition of differentiation and promotion of proliferation, Pigment Cell & Melanoma Research, vol.57, issue.Pt 3, pp.773-84, 2009.
DOI : 10.1111/j.1755-148X.2009.00616.x

B. Schoeberl, E. Pace, J. Fitzgerald, B. Harms, L. Xu et al., Therapeutically Targeting ErbB3: A Key Node in Ligand-Induced Activation of the ErbB Receptor-PI3K Axis, Science Signaling, vol.2, issue.77, p.31, 2009.
DOI : 10.1126/scisignal.2000352

B. Schoeberl, A. Faber, D. Li, M. Liang, K. Crosby et al., An ErbB3 Antibody, MM-121, Is Active in Cancers with Ligand-Dependent Activation, Cancer Research, vol.70, issue.6, pp.2485-94, 2010.
DOI : 10.1158/0008-5472.CAN-09-3145

G. Schaefer, L. Haber, L. Crocker, S. Shia, L. Shao et al., A Two-in-One Antibody against HER3 and EGFR Has Superior Inhibitory Activity Compared with Monospecific Antibodies, Cancer Cell, vol.20, issue.4, pp.472-86, 2011.
DOI : 10.1016/j.ccr.2011.09.003

L. Aurisicchio, E. Marra, L. Luberto, F. Carlomosti, D. Vitis et al., Novel anti-ErbB3 monoclonal antibodies show therapeutic efficacy in xenografted and spontaneous mouse tumors, Journal of Cellular Physiology, vol.104, issue.10, 2011.
DOI : 10.1002/jcp.24037

J. Spangler, J. Neil, S. Abramovitch, Y. Yarden, F. White et al., Combination antibody treatment down-regulates epidermal growth factor receptor by inhibiting endosomal recycling, Proceedings of the National Academy of Sciences, vol.107, issue.30, pp.13252-13259, 2010.
DOI : 10.1073/pnas.0913476107

L. Friedman, A. Rinon, B. Schechter, L. Lyass, S. Lavi et al., Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: Implications for cancer immunotherapy, Proceedings of the National Academy of Sciences, vol.102, issue.6, pp.1915-1935, 2005.
DOI : 10.1073/pnas.0409610102

T. Ben-kasus, B. Schechter, S. Lavi, Y. Yarden, and M. Sela, Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: Relevance of receptor endocytosis, Proceedings of the National Academy of Sciences, vol.106, issue.9, pp.3294-3303, 2009.
DOI : 10.1073/pnas.0812059106

A. Sorkin and L. Goh, Endocytosis and intracellular trafficking of ErbBs, Experimental Cell Research, vol.315, issue.4, pp.3093-10618793634, 2008.
DOI : 10.1016/j.yexcr.2008.07.029

H. Kaufman, The melanoma book, a complete guide to prevention and treatment. Penguin Group: USA, 2005.

F. Hodi, O. Day, S. Mcdermott, D. Weber, R. Sosman et al., Improved Survival with Ipilimumab in Patients with Metastatic Melanoma, New England Journal of Medicine, vol.363, issue.8, pp.711-734, 2010.
DOI : 10.1056/NEJMoa1003466

P. Chapman, A. Hauschild, C. Robert, J. Haanen, P. Ascierto et al., Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation, New England Journal of Medicine, vol.364, issue.26, pp.2507-2523, 2011.
DOI : 10.1056/NEJMoa1103782

P. Poulikakos and N. Rosen, Mutant BRAF Melanomas???Dependence and Resistance, Cancer Cell, vol.19, issue.1, 2011.
DOI : 10.1016/j.ccr.2011.01.008

URL : http://doi.org/10.1016/j.ccr.2011.01.008

G. Lurje and H. Lenz, EGFR Signaling and Drug Discovery, Oncology, vol.77, issue.6, pp.400-410, 2009.
DOI : 10.1159/000279388

M. Lemmon and J. Schlessinger, Cell Signaling by Receptor Tyrosine Kinases, Cell, vol.141, issue.7, pp.1117-1151, 2010.
DOI : 10.1016/j.cell.2010.06.011

H. Zhang, A. Berezov, Q. Wang, G. Zhang, J. Drebin et al., ErbB receptors: from oncogenes to targeted cancer therapies, Journal of Clinical Investigation, vol.117, issue.8, pp.2051-2059, 2007.
DOI : 10.1172/JCI32278

J. Baselga and S. Swain, Novel anticancer targets: revisiting ERBB2 and discovering ERBB3, Nature Reviews Cancer, vol.25, issue.7, pp.463-75, 2009.
DOI : 10.1038/nrc2656

A. Citri, K. Skaria, and Y. Yarden, The deaf and the dumb: the biology of ErbB-2 and ErbB-3, Experimental Cell Research, vol.284, issue.1, pp.54-65, 2003.
DOI : 10.1016/S0014-4827(02)00101-5

M. Olayioye, R. Neve, H. Lane, and N. Hynes, NEW EMBO MEMBERS' REVIEW: The ErbB signaling network: receptor heterodimerization in development and cancer, The EMBO Journal, vol.19, issue.13, pp.3159-67, 2000.
DOI : 10.1093/emboj/19.13.3159

M. Alimandi, A. Romano, M. Curia, R. Muraro, P. Fedi et al., Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas, Oncogene, vol.10, pp.1813-217538656, 1995.

T. Holbro, R. Beerli, F. Maurer, M. Koziczak, C. Barbas et al., The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation, Proceedings of the National Academy of Sciences, vol.100, issue.15, pp.8933-8941, 2003.
DOI : 10.1073/pnas.1537685100

J. Engelman, K. Zejnullahu, T. Mitsudomi, Y. Song, C. Hyland et al., MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling, Science, vol.316, issue.5827, pp.1039-1082, 2007.
DOI : 10.1126/science.1141478

J. Garrett, M. Olivares, C. Rinehart, N. Granja-ingram, V. Sánchez et al., Transcriptional and posttranslational upregulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase, Proc Natl Acad Sci, 2011.